Gyre Therapeutics (GYRE) Stock Forecast: StockMap's 2-Week Call
GYRE stock forecast: StockMap's model makes no two-week call on Gyre Therapeutics after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Too few two-week windows graded to judge yet.
Gyre Therapeutics last closed at $4.52, +4.15% on the session.
Against the IVW growth benchmark the position is +6.48% over the forecast window.
Gyre Therapeutics' market cap is $494.74M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 13 (too close to call).
Where GYRE sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 33%.
3 daily calls for GYRE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Gyre Therapeutics in the 24th percentile on return on equity, where 100 is best.
Gyre Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Gyre Therapeutics as the 173rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Gyre Therapeutics ranks 32nd of 394 in the group, against a group median of -0.27.